This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Sep 1;140(9):908.

doi: 10.1001/jamaophthalmol.2022.2612.

In Defense of Phosphodiesterase 5 Inhibitors

Federico Belladelli¹, Francesco Del Giudice², Michael L Eisenberg³

Affiliations

Affiliations

¹ Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
² Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Rome, Italy.
³ School of Medicine, Department of Urology, Stanford University, California.

PMID: 35862053
DOI: 10.1001/jamaophthalmol.2022.2612

Comment

In Defense of Phosphodiesterase 5 Inhibitors

Federico Belladelli et al. JAMA Ophthalmol. 2022.

. 2022 Sep 1;140(9):908.

doi: 10.1001/jamaophthalmol.2022.2612.

Authors

Federico Belladelli¹, Francesco Del Giudice², Michael L Eisenberg³

Affiliations

¹ Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
² Department of Maternal Infant and Urologic Sciences, Sapienza University of Rome, Rome, Italy.
³ School of Medicine, Department of Urology, Stanford University, California.

PMID: 35862053
DOI: 10.1001/jamaophthalmol.2022.2612

No abstract available

PubMed Disclaimer

Comment in

In Defense of Phosphodiesterase 5 Inhibitors-Reply.
Sodhi M, Mikelberg FS, Etminan M. Sodhi M, et al. JAMA Ophthalmol. 2022 Sep 1;140(9):908-909. doi: 10.1001/jamaophthalmol.2022.2615. JAMA Ophthalmol. 2022. PMID: 35862036 No abstract available.

Comment on

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.
Etminan M, Sodhi M, Mikelberg FS, Maberley D. Etminan M, et al. JAMA Ophthalmol. 2022 May 1;140(5):480-484. doi: 10.1001/jamaophthalmol.2022.0663. JAMA Ophthalmol. 2022. PMID: 35389459 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems